Prospective randomized comparison of oral sodium phosphate and polyethylene glycol lavage for colonoscopy preparation

Table 6 Occurrence and severity of anticipated adverse events

	NaP (n = 40)				PEG (n = 40)
	Mild	Moderate	Severe	Occurrence (%)1	Mild	Moderate	Severe	Occurrence (%)1	P2
Nausea	17	0	1	18 (45)	14	4	0	18 (45)	1.000
Vomiting	9	1	0	10 (25)	5	4	0	9 (22.5)	1.000
Abdominal bloating	16	2	0	18 (45)	12	0	0	12 (30)	0.248
Abdominal pain	14	1	1	16 (40)	11	0	0	11 (27.5)	0.344
Anal irritation	13	3	0	16 (40)	10	1	1	12 (30)	0.482
Dizziness	13	2	1	16 (40)	10	1	0	11 (27.5)	0.344
Chills	3	0	1	4 (10)	3	0	0	3 (7.5)	1.000
Hunger pains	7	0	0	7 (17.5)	7	0	0	7 (17.5)	1.000
Headache	6	1	0	7 (17.5)	6	0	0	6 (15)	1.000
Insomnia3	4	1	0	5 (12.8)	2	0	0	2 (5)	0.263
Total	11	4	117	11	80	10	1	91

¹Occurrence rate was calculated by “frequency of occurrence/total number of subject”. ²Fisher’s exact test for occurrence frequency of adverse events.

³One patient in NaP group was taking Lorazepan (Ativan, Wyeth, USA) for insomnia during the bowel preparation, therefore this event was not assessable for this patient.